Risk factors, aetiology, therapy and outcome in 123 episodes of breakthrough bacteraemia and fungaemia during antimicrobial prophylaxis and therapy in cancer patients

Journal of Medical Microbiology

Volumn 46, Issue 6, 1997, Pages 517-523

  Spanik, S ^a   Trupl, J ^d   Kunova, A ^b   Drgona, L ^c   Salek, T ^a   Mardiak, J ^a   Kukuckova, E ^c   Studena, M ^b   Pichna, P ^c   Oravcova, E ^a   Grey, E ^a   Koren, P ^b   Svec, J ^d   Lacka, J ^a   Sufliarsky, J ^a   Krcmery, V ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b TRNAVA UNIVERSITY   (Slovakia)

^c Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^d Physics and Informatics   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; AZLOCILLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; FLUCONAZOLE; GENTAMICIN; IMIPENEM; ITRACONAZOLE; NETILMICIN; OFLOXACIN; PEFLOXACIN; PIPERACILLIN; SULTAMICILLIN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CORYNEBACTERIUM; ENTEROCOCCUS FAECALIS; FUNGEMIA; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK FACTOR; STAPHYLOCOCCUS;

EID: 8244239690     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-46-6-517     Document Type: Article

References (20)

1. HORTC Antimicrobial Therapy Group. Prospective comparison of three antibiotic regimens for empirical therapy of suspected infection in febrile granulocytopenia patients. J Infect Dis 1978; 137: 22-29
2. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987; 317: 1692- 1698.
3. EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada - Clinical Trials Group Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-958.
4. Meunier F, Zinner SH, Gaya H and the EORTC Antimicrobial Therapy Group. Prospective randomized evaluation of ciproHoxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Anitimicrob Agents Chemother 1991; 35: 873-878.
5. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and cetriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-593.
6. RORTC International Antimicrobial Therapy Cooperative Group. A prospective double blind study of pefloxacin plus penicillin or placebo for prophylaxis of bacterial infections in granulocytopenic cancer patients. 32nd ICAAC, Anaheim. 1992. Abstract no. 1692.
7. Gaya H, and the International Antimicrobial Therapy Cooperative Group. Piperacillin/tazobactam plus amikacin versus ceftazidime plus amikacin as empirical therapy for fever in patients with granulocytopenia. 33rd ICAAC, New Orleans. 1993. Abstract no. 645.
8. International Antimicrobial Therapy Cooperative Group of the EORTC. A randomized study on meropenem versus ceftazidim plus amikacin in febrile granulocytopenic patients. Abstracts. 34th ICAAC, Orlando. 1994. Abstract no. 1193.
9. Kern W, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 39: 681-687.
10. Cometta A. Calandra T, Bille T, Galazzo J, Giddey M, Glauser M. Quinolone resistant Escherichia coli bacteraemias in neutropenic cancer patients. Proceedings of the IHS Symposium. Davos, 1994. Abstract no. 84.
11. Carratala J. Fernandez-Swilla A, Tuhau F, Callis M, Gudiol F. Emergence of quinolone resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557-560.
12. Noskin GA, Peterson LR, Warren JR, Enterococcus faecium and Enterococcus faecalis bacteraemia: acquisition and outcome. Clin Infect Dis 1995; 20: 296-301.
13. Bochud P, Eggimann P, Calandra T, Van Melle G, Saghafi L, Franciol P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 25.
14. Krc̀méry V, Trupl J. Nosocomial outbreak of meropenem resistant Pseudomonas aeruginosa infections in a cancer centre. J Hosp Infect 1994; 26: 69-71.
15. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Sarah R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-1277.
16. Viscoli C, Surveillance of fungaemias in cancer centres. EORTC study. Abstracts, 6th BICON Annual Meeting, Bratislava. 1995. Abstract no. 33; 19.-23.3.
17. Chow J, Fine M, Shlaes DM et al. Enterobacter bacteraemia: clinical features and emergence of antibiotic resistance during therapy. Ann Infect Med 1991; 115: 585-590.
18. Rosenthal EJK. [Epidemiologie von Septikämie-Erregen. Blutkulturstudie der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V.] Dtsch Med Wochenschr 1993; 118: 1269-1275.
19. Lecciones J, Lee J, Navarro E et at. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992; 16: 875.
20. Tilley G, Roberts F. Bacteremia with Acinotobacter species: risk factors and prognosis in different clinical settings, Clin Infect Dis 1994; 18: 896-900.